← 產業報告目錄

Avascular Necrosis Market, By Drug Type (Nonsteroidal anti-inflammatory drugs (Ibuprofen, Naproxen Sodium), Osteoporosis drugs, Cholesterol-lowering drugs, Blood thinners, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版商 Coherent Market Insights出版日期 2026-07-17頁數 259報告編號 CMR-ddf47acef1

授權報價

Single User Price$4,500 USD
Site License Price$7,000 USD
Enterprisewide Price (Global Site License)$10,000 USD
洽詢購買 申請 Sample

報告摘要

Avascular necrosis is a disease that results from the short-term or permanent loss of blood supply to the bone. This cut-off of blood supply to bone leads to tiny breaks in the bone and the bones eventually collapse. Avascular necrosis is also known as osteonecrosis. This condition may happen in any bone of the body, but mostly happens in the ends of a long bone. A broken bone or dislocated joint can interrupt the blood flow to a section of bone. Avascular necrosis condition is most common in people between the ages of 30 and 50. Avascular necrosis can be caused due to- • Injury to bone • Fracture • Damage of blood vessels • Long-term use of medicines, such as corticosteroids • Excessive, long-term use of alcohol Avascular necrosis can be diagnosed by Bone scan, Magnetic Resonance Image and Computed Tomography, and X-rays. Medications used to treat avascular necrosis are blood thinners, nonsteroidal anti-inflammatory drugs, cholesterol lowering drugs and others. Market Dynamics Increasing number of product launches is expected to drive the growth of global avascular necrosis market during the forecast period. For instance, in September 2014, Bayer Healthcare LLC, a pharmaceutical and medicine manufacturing company, announced the launch of Aleve PM, an over-the-counter (OTC) pain reliever product in the U.S. Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global avascular necrosis market. For instance, in April 2019, the U.S Food and Drugs Administration approved Evenity (romosozumab-aqqg), a sclerostin inhibitor indicated to treat osteoporosis in postmenopausal women at high risk of breaking a bone. Key features of the study • This report provides an in-depth analysis of the global avascular necrosis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players • It profiles leading players in the global avascular necrosis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Solara Active Pharma Sciences Limited., Bayer AG, Rochem International, Inc., Alkem Labs., Dwarkesh Pharmaceuticals Private Limited., Novartis AG, GSK, and Pfizer Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics • The global avascular necrosis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global avascular necrosis market Market Segmentation • By Drug Type Insights (Revenue, USD Mn, 2021 - 2033) o Nonsteroidal anti-inflammatory drugs (Ibuprofen, Naproxen Sodium) o Osteoporosis Drugs o Cholesterol-lowering Drugs o Blood Thinners o Others • By Route of Administration Insights (Revenue, USD Mn, 2021 - 2033) o Oral o Injectable • By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  North Africa  South Africa  Central Africa • Key Players in the Avascular Necrosis Market o Teva Pharmaceutical Industries Ltd. o Reddy’s Laboratories Ltd. o Solara Active Pharma Sciences Limited o Bayer AG o Rochem International Inc. o Alkem labs. o Dwarkesh Pharmaceuticals Private Limited. o Novartis AG o GSK o Pfizer, Inc.
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Overview o Report Description  Market Definition and Scope o Executive Summary  Market Snippet, By Drug Type  Market Snippet, By Distribution Channel  Market Snippet, By Route of Administration  Market Snippet, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Drivers o Restraints o Market Opportunities o Impact Analysis o Market Trends o Recent Product Launches/Approvals o Regulatory Scenario o Epidemiology o PEST Analysis o Acquisition and Collaboration Scenario 4. Global Avascular Necrosis Market, By Drug Type, 2021 – 2033 (USD Million) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Nonsteroidal anti-inflammatory drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Ibuprofen o Naproxen Sodium o Osteoporosis drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Cholesterol-lowering drugs  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Blood Thinners  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) 5. Global Avascular Necrosis Market, By Route of Administration, 2021 – 2033 (USD Million) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Oral  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Injectable  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) 6. Global Avascular Necrosis Market, By Distribution Channel, 2021 – 2033, (USD Million) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 – 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (USD Million) 7. Global Avascular Necrosis Market, By Region, 2021 – 2033, (USD Million) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, By Region, 2022 – 2033  Regional Trends o North America  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o U.S. o Canada o Europe  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o China o Japan o India o ASEAN o Australia o South Korea o Rest of APAC o Latin America  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o Brazil o Mexico o Argentina o Rest of Latin America o Middle East  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o GCC o Israel o Rest of Middle East o Africa  Market Size and Forecast, By Drug Type, 2021 – 2033, (USD Million)  Market Size and Forecast, By Route of Administration 2021 – 2033, (USD Million)  Market Size and Forecast, By Distribution Channel, 2021 – 2033, (USD Million)  Market Size and Forecast, By Country, 2021 – 2033, (USD Million) o North Africa o Central Africa o South Africa 8. Competitive Landscape o Company Profiles  Teva Pharmaceuticals Industries Ltd. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Dr. Reddy’s Laboratories Ltd. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Solara Active Pharma Sciences Limited. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Bayer AG o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Rochem International, Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Alkem Labs. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Dwarkesh Pharmaceuticals Private Limited o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Novartis AG o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  GSK o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies  Pfizer, Inc. o Company Overview o Product Portfolio o Financial Performance o Recent Highlights o Strategies 9. Section o References o Research Methodology o About us and Sales Contact
圖表清單 List of Tables & Figures
NA NA

提及公司

o Teva Pharmaceutical Industries Ltd.o Reddy’s Laboratories Ltd.o Solara Active Pharma Sciences Limitedo Bayer AGo Rochem International Inc.o Alkem labs.o Dwarkesh Pharmaceuticals Private Limited.o Novartis AGo GSKo PfizerInc.

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們